Ravulizumab is now available in a more concentrated formulation (100 mg/ml compared to 10 mg/ml previously). The new formulation significantly shortens the infusion time while maintaining safety and efficacy. Previously, the infusion took at least two hours, but with the new formulation it will be about 60% faster on average, depending on the dose and weight of the patient. It became available as an infusion on 5 January 2021.
